Real-time continuous in vivo drug monitoring

Dear All: 

I recently became aware of a technology for real-time continuous in vivo monitoring of drug levels that I thought worth sharing with the broader community. Although we’ve for many years had continuous measures of analytes such as glucose or oxygen where simple chemistry gave a suitable measurement tool, measurement of arbitrary analytes has not previously been something that could be readily achieved.

As described in a new PNAS paper by Arroyo-Currás et al., there is now a technology that addresses this challenge. The idea starts with noting that aptamers (oligonucleotides with high affinity for specific molecules) undergo a conformational change when they bind their target. This change can be detected electrochemically if the aptamer is bound to a suitable electrode. In addition, Jennifer Hoover (GSK) and Kevin Plaxco (originator of the technology) have written a white paper that you can review for additional details.

While we’ve managed to work for many years with blood level monitoring using the sample-and-test strategy, the idea of being able to get instant levels is fascinating and might simplify some aspects of drug R&D. Many thanks for Jenn & Kevin for bringing this to my attention. Kevin would be happy to be contacted at kwp@chem.ucsb.edu if you’d like to explore ways to collaborate with him.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Scroll to Top